Although intravesical therapy with bacillus Calmette-Guérin (BCG) has proven its efficiency in the treatment of early-stage bladder cancer, infectious complications can occur and mycotic aneurysms represent a rare but life-threatening complication. Here, we report the case of an aortic graft infection in a patient with abdominal aortic aneurysm who received BCG instillations for the treatment of bladder cancer. Based on the current knowledge on this rare vascular complication, we discuss factors that may have contributed to its occurrence and review issues to optimize its management and early detection.
AlexandroffABJacksonAMO’DonnellMAJamesK. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):1689–1694.
2.
LammDLvan der MeijdenPMMoralesA. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600.
3.
KoyaMPSimonMASolowayMS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004–2010.
4.
BabjukMBurgerMZigeunerR; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–653.
5.
MoralesAEidingerDBruceAW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183.
6.
PrescottSJacksonAMHawkyardSJAlexandroffABJamesK. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis. 2000;31(suppl 3):S91–S93.
7.
Vazquez-LavistaLGFlores-BalcazarCHLlorenteL. The bacillus Calmette-Guerin as immunomodulator in bladder cancer [in Spanish]. Rev Invest Clin. 2007;59(2):146–152.
8.
SchellhammerPFKaplanMHPinskyCMWhitmoreWFJr. Study of local and systemic effects of intravesical BCG. Urology. 1975;6(5):562–567.
9.
LammDLStogdillVDStogdillBJCrispenRG. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol. 1986;135(2):272–274.
10.
LammDL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31(suppl 3):S86–S90.
11.
Torres-BlancoAGomez-PalonesFEdo-FletaG. Arteriocutaneous fistula associated with bilateral femoral pseudoaneurysms caused by bacillus Calmette-Guerin. Apropos of a case and review of literature. Ann Vasc Surg. 2017;39:291.e1–291.e6.
12.
DavisFMMillerDJNewtonDAryaSEscobarGA. Successful treatment of a mycotic multifocal thoracoabdominal aortic aneurysm as a late sequelae of intravesical bacillus Calmette-Guerin therapy: case report and literature review. Ann Vasc Surg. 2015;29(4):840.e9–13.
13.
ElkabaniMGreeneJNVincentALVanHookSSandinRL. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Gu rin treatments for bladder cancer. Cancer Control. 2000;7(5):476–481.
14.
HardingGELawlorDK. Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guerin. J Vasc Surg. 2007;46(1):131–134.
15.
MizoguchiHIidaODohiT. Abdominal aortic aneurysmal and endovascular device infection with iliopsoas abscess caused by Mycobacterium bovis as a complication of intravesical bacillus Calmette-Guerin therapy. Ann Vasc Surg. 2013;27(8):1186.e1–5.
16.
WolfYGWolfDGHigginbottomPADilleyRB. Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Guerin after intravesical administration for bladder cancer. J Vasc Surg. 1995;22(1):80–84.
17.
SantbergenBVriensPHde LangeWCVan KasterenME. Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment. BMJ Case Rep. 2013;2013:bcr2012008161.
18.
Truffot-PernotCVezirisN. Bacteriological tests for tuberculosis [in French]. Rev Mal Respir. 2011;28(8):1034–1047.
19.
van der MeijdenAP. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol. 1995;27(suppl 1):23–28.
20.
Perez-Jacoiste AsinMAFernacdndez-RuizMLopez-MedranoF. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236–254.
21.
RoylanceAMosleyJJameelMSylvanAWalkerV. Aorto-enteric fistula development secondary to mycotic abdominal aortic aneurysm following intravesical bacillus Calmette-Guerin (BCG) treatment for transitional cell carcinoma of the bladder. Int J Surg Case Rep. 2013;4(1):88–90.
